Compare Honest Company Inc (HNST) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs Viatris Inc — how do they compare? Honest Company Inc trades at $3.83 (market cap $427.66M), while Viatris Inc trades at $17.05 (market cap $20.50B). The key difference: Viatris Inc is far larger — about 47.9× Honest Company Inc's market cap, and Viatris Inc pays a 2.73% dividend while Honest Company Inc pays none. Which is the better fit depends on your goals.
| HNST | VTRS | |
|---|---|---|
Market Cap | $427.66M | $20.50B |
Sector | Consumer Staples | Health |
52-Week High | $4.95 | $17.59 |
52-Week Low | $2.10 | $8.74 |
Enterprise Value | $349.05M | $32.71B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $3.89, up 1.57% with a bullish technical signal. The company shows mixed fundamentals with revenue of $371.32M in 2025 but negative net income of -$15.69M. Recent earnings show one beat and two misses, while cash flow improved to $14.15M net. Analyst consensus is divided with 30% buy, 50% hold ratings. The company announced Q2 2026 results for August 5, 2026, alongside leadership updates.
Outlook remains cautious due to persistent losses and margin pressure, though strategic shifts to retail and cost controls offer potential. Key risks include competitive intensity and execution challenges. The stock presents speculative appeal for turnaround believers but requires monitoring of profitability improvements.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
